Standard BioTools Inc (NASDAQ:LAB) price closed higher on Monday, March 25, jumping 0.75% above its previous close.
A look at the daily price movement shows that the last close reads $2.68. The company’s 5Y monthly beta was ticking 1.62. Taking into account the 52-week price action we note that the stock hit a 52-week high of $3.16 and 52-week low of $1.46. The stock added 10.20% on its value in the past month.
Standard BioTools Inc, which has a market valuation of $783.32 million, is expected to release its quarterly earnings report May 07, 2024 – May 13, 2024.
Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give LAB a short term outlook of 100% Buy on average. Looking at the stock’s medium term indicators we note that it is averaging as a 100% Buy, while an average of long term indicators are currently assigning the stock as 50% Buy.
The overview shows that LAB’s price is at present 4.83% off the SMA20 and 10.33% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 59.05, with weekly volatility standing at 5.39%. The indicator jumps to 6.26% when calculated based on the past 30 days. Standard BioTools Inc (NASDAQ:LAB)’s beta value is holding at 1.63, while the average true range (ATR) indicator is currently reading 0.15.
An analysis of the Standard BioTools Inc (NASDAQ:LAB) stock in terms of its daily trading volume indicates that the 3-month average is 1.84 million.
Current records show that the company has 290.12M in outstanding shares. The insiders’ percentage holdings are 2.56% of outstanding shares while the percentage share held by institutions stands at 47.78%. But the 22.17% upside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.
